Novartis' repurposed cancer drug Arzerra outpaces Sanofi's Aubagio in multiple sclerosis trial

30th August 2019 Uncategorised 0

Novartis laid out $16 billion for GlaxoSmithKline’s oncology portfolio in 2015 and spent much of the last four years laboring to make Arzerra a success. It hasn’t been lucky yet, but hopes fresh phase 3 data will help it move into multiple sclerosis.

More: Novartis' repurposed cancer drug Arzerra outpaces Sanofi's Aubagio in multiple sclerosis trial
Source: fierce